COVID-19 Variants | Order Biospecimens Online

New COVID-19 Variants are on the rise

Banner New COVID19 variants are on the rise

New COVID19 variants are on the rise

New COVID19 variants are on the rise

During and after the pandemic, one of the biggest challenges in the fight against the SARS-CoV-2 virus is the emergence of variants, each with a unique genetic fingerprint and implications for COVID-19 vaccines and diagnostic tests.

SARS-CoV-2 variants come along with various names that are often related to the regions where they first emerged. Most known variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) among others. New variants emerged since the end of 2022, namely XB.1.5. or EG.5. They differ in distinct genetic mutations that can impact the behavior of the virus, resulting in increased transmissibility or better resistance to the human immune system, even after an early infection or prior to vaccination.

Understanding the differences between these variants is critical for evaluating their potential impact on public health. For instance, the Alpha variant, which had been identified first in the United Kingdom, was associated with an improved transmissibility. In contrast, the Beta variant, first found in South Africa, raised concerns regarding its high resistance to certain antibodies that have their origin in past COVID-19 infections or vaccinations.

Originating in India, the Delta variant gained global attention due to its remarkable transmissibility and potential to evade immune responses under certain conditions. These differences highlight the urgency of adjusting vaccination strategies to address these uprising variants.

The influence of COVID19 variants on diagnostic tests

Additionally, these variants can also influence the accuracy of COVID-19 diagnostic tests, such as PCR and antigen tests. Some mutations in the virus's genetic code may affect the ability and accuracy of these tests to detect the presence of the virus. As a result, diagnostic test developers constantly monitor the genetic profile of circulating variants to ensure their tests are up to date.

Central BioHub offers more than 30,000 biospecimens from COVID-19 vaccinated donors that can help to develop specific diagnostic tests targeting key genetic markers that are unique to certain variants. All Saliva samples originate from donors who had been vaccinated with various COVID-19 vaccines from known companies and all donors had previously been tested for SARS-CoV-2. Thus, our COVID-19 Vaccinated Donor Samples give researchers the perfect opportunity to validate their existing diagnostic tests or develop variant adapted tests for the future. Have a peek at our large assortment of biospecimens and reserve your samples for free:

  • COVID-19 Vaccinated Donor Saliva Samples:

Instant access to specimen information, fast and easy shipping and a scientific customer support that will answer all your questions make Central BioHub the number one online marketplace for human biomaterials. Browse the biggest catalog for biospecimens and find the samples that best meet your needs by clicking on clinical diagnosis, ICD-10-CM codes, and laboratory parameters.
Central BioHub - Order biospecimens online.

Since the official end of the pandemic, the Omicron variant XBB.1.5. and its subvariant EG.5 (Eris) are the predominant virus types, responsible for most COVID-19 infections.
The Salvia Samples from COVID-19 Vaccinated Donors in our catalogue were procured as clinical remnant samples in the process of testing patients for SARS-CoV-2. All donors received at least one shot of one of the major COVID-19 vaccines provided by various known pharmaceutical companies. These samples are optimal for usage in diagnostic research studies or for COVID-19 vaccine development.
There are three prominent COVID-19 test methods, namely PCR, antigen, and antibody tests. PCR tests detect the viruss genetic material directly and are highly accurate. Antigen tests detect specific viral proteins very rapidly but are less sensitive. Antibody tests can be used to check for past infections by detecting antibodies in the blood.
The accuracy of COVID-19 tests varies depending on the type of tests, the timing between the first infection symptoms and the presence of variants. Central BioHub is eager to improve the accuracy of COVID-19 tests by supplying our customers with COVID-19 samples from vaccinated donors, that can help diagnostic researchers to validate and improve their SARS-CoV-2 tests.